Kimby Barton received her Undergraduate and Master's degree in Science from the University of Guelph. She spent four years working on a Doctorate in Biochemistry at the University of Toronto before leaving her studies to take a position as Associate Editor and Head of Strategic Development at a small medical publishing company. Ms. Barton joined Health Canada in 2002 as an Evaluator and then Manager with the Marketed Pharmaceuticals and Medical Devices Bureau (MPMDB) of the Marketed Health Products Directorate (MHPD). At MHPD, Kimby was involved with development of Methodologies for signal prioritization and signal assessment, and participated in a number of policy initiatives including development of guidance for risk communications and hepatotoxicity. Most recently Kimby has been involved in discussions on the Modernization of the Food and Drugs Acts, as well as development of a Product Vigilance Framework. She is also currently the chair of the Health Portfolio Risk Management Planning Working Group, and a member of the Health Products and Food Branch Clinical Safety and Efficacy Committee. Kimby is currently the Director of the Bureau of Cardiology, Allergy, and Neurological Sciences in the Therapeutic Products Directorate.